The mutation hotspots analyzed in our study should cover more than 90% of bladder-cancer-relevant gain-of-function mutations of the FGFR3 gene [13] and ~80% of TERT promoter mutations [22], respectively. This evidence concerns the gene FGFR3 and urinary bladder cancer.